Whalesbook
Aurobindo Pharma ke shares mein aaj National Stock Exchange (NSE) par 7% tak ki girawat dekhne ko mili, jab company ne fiscal year 2026 ke fourth quarter ke financial results announce kiye. Company ne consolidated profit after tax mein 2% ka modest jump dikhate hue ₹920.84 Crore ka profit report kiya. Lekin, investors ki nazar profit margins mein hui kami par thi.
Margin Contraction Ne Investors Ko Pareshaan Kiya
Pharma company ne January-March quarter ke liye ₹8,853.34 Crore ka total consolidated revenue report kiya, jo pichhle saal ke same quarter ke ₹8,382.12 Crore se zyada hai. Halanki, kharche bhi ₹7,677.34 Crore tak badh gaye, jo pehle ₹7,149.65 Crore the. Earnings before interest, taxes, depreciation, and amortization (Ebitda) mein 0.5% ka year-on-year growth dekha gaya, jo ₹1,801 Crore raha. Sabse badi baat ye hai ki Ebitda margins 103 basis points kam hokar 20.3% ho gaye, jabki pichhle saal ye 21.4% the. Yehi girawat stock girne ki main wajah lag rahi hai.
US Business Mein Kamzori Jaari Hai
Aurobindo Pharma ne bataya ki US formulation business mein quarter ke dauraan slowdown raha. Is segment se revenue 13% year-on-year gir kar ₹3,543 Crore ho gaya, jo pehle ₹4,072 Crore tha. US market aam taur par Aurobindo Pharma ke total revenue ka lagbhag 40% contribute karta hai, aur sales mein yeh kami lower transient sales ke karan batayi ja rahi hai.
Europe Ki Performance Ne US Ki Kami Ko Poora Kiya
US market ke vipreet, Aurobindo Pharma ke European formulation business ne zabardast growth dikhai. Is region se revenue 30.2% year-on-year badh kar ₹2,795 Crore ho gaya, jismein uske main European markets mein solid performance ka yogdaan raha. Aurobindo Pharma 150 se zyada deshon mein globally operate karti hai, aur generic aur branded pharmaceuticals, saath hi active pharmaceutical ingredients ki development, manufacturing, aur marketing par focus karti hai.